Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single arm, open label, signal seeking, phase IIa trial of the activity of eribulin in patients with advanced CD31 positive angiosarcoma and selected CD31 positive sarcomas

Trial Profile

Single arm, open label, signal seeking, phase IIa trial of the activity of eribulin in patients with advanced CD31 positive angiosarcoma and selected CD31 positive sarcomas

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 29 May 2018

At a glance

  • Drugs Eribulin (Primary)
  • Indications Haemangioendothelioma; Haemangiosarcoma; Sarcoma
  • Focus Therapeutic Use
  • Acronyms MoST Addendum 5
  • Most Recent Events

    • 24 May 2018 Planned initiation date changed from 1 Jun 2018 to 1 Sep 2018.
    • 25 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top